Introduction: The presence of liver cirrhosis can have a major impact on pharmacodynamics and pharmacokinetics, but guidance for prescribing is lacking.
Objective: The aim of this study is to provide an overview of evidence-based recommendations developed for the safe use of drugs in liver cirrhosis.
Methods: Recommendations were based on a systematic literature search combined with expert opinion from a panel of 10 experts. The safety of each drug was classified as safe, no additional risks known, additional risks known, unsafe, unknown or the safety class was dependent on the severity of liver cirrhosis (Child-Pugh classification). If applicable, drug-specific dosing advice was provided. All recommendations were implemented in clinical decision support systems and on a website.
Results: We formulated 218 recommendations for a total of 209 drugs. For nine drugs, two recommendations were formulated for different administration routes or indications. Drugs were classified as 'safe' in 29 recommendations (13.3%), 'no additional risks known' in 60 (27.5%), 'additional risks known' in 3 (1.4%), and 'unsafe' in 30 (13.8%). In 57 (26.1%) of the recommendations, safety depended on the severity of liver cirrhosis and was 'unknown' in 39 (17.9%) recommendations. Large alterations in pharmacodynamics were the main reason for classifying a drug as 'unsafe'. For 67 drugs (31%), a dose adjustment was needed.
Conclusions: Over 200 recommendations were developed for the safe use of drugs in patients with liver cirrhosis. Implementing these recommendations into clinical practice can possibly enhance medication safety in this vulnerable patient group.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966501 | PMC |
| http://dx.doi.org/10.1007/s40264-017-0635-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic accuracy of two-dimensional shear wave elastography and point shear wave elastography in identifying different stages of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: A meta-analysis.
Biomol Biomed
January 2025
Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
To assess the diagnostic accuracy of two-dimensional shear wave elastography (2-D SWE) and point shear wave elastography (pSWE) in detecting liver fibrosis stages in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), a comprehensive search was conducted across four databases up to February 9, 2024. A bivariate random-effects model was used to analyze the diagnostic accuracy of the methods. After screening, 13 studies involving pSWE included 1527 patients, while nine studies involving 2-D SWE included 1088 patients.
View Article and Find Full Text PDFKnowledge, Attitude, and Practice Toward Liver Fibrosis/Cirrhosis and Traditional Chinese Medicine Treatment Among Medical Staff.
J Eval Clin Pract
February 2025
Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
Rationale: Liver fibrosis is a critical stage in the progression from liver injury to cirrhosis or tumor formation. Traditional Chinese medicine (TCM) has shown certain effectiveness in treating liver fibrosis. However, there is currently a lack of knowledge, attitude, and practice (KAP) studies regarding this topic.
View Article and Find Full Text PDFPredictive Value of Serum Lactate Levels for Mortality in Patients with Hepatitis B-Related Decompensated Cirrhosis: A Retrospective Analysis.
Br J Hosp Med (Lond)
December 2024
Department of Gastroenterology, The Second People's Hospital of Quzhou, Quzhou, Zhejiang, China.
Decompensated cirrhosis is characterized by the progression of cirrhosis from an asymptomatic state to elevated portal pressure and marked deterioration of liver function. This pathological condition progresses rapidly following onset, significantly raising the risk for mortality. The aim of this study is to explore the association between serum lactate concentrations and mortality rates in individuals with hepatitis B-induced decompensated cirrhosis and to evaluate its potential as a clinical prognostic indicator.
View Article and Find Full Text PDFTargeting microRNA methylation: Innovative approaches to diagnosing and treating hepatocellular carcinoma.
Noncoding RNA Res
April 2025
Bashkir State Medical University, Ufa, Republic of Bashkortostan, 3 Lenin Street, 450008, Russia.
Hepatocellular carcinoma (HCC) stands as the most prevalent form of primary liver cancer and is frequently linked to underlying chronic liver conditions such as hepatitis B, hepatitis C, and cirrhosis. Despite the progress achieved in the field of oncology, HCC remains a significant clinical challenge, primarily due to its typically late-stage diagnosis and the complex and multifaceted nature of its tumor biology. These factors contribute to the limited effectiveness of current treatment modalities and result in poor patient prognosis.
View Article and Find Full Text PDFRisk of hepatocellular carcinoma in Asian patients with primary biliary cholangitis: A nationwide and hospital cohort study.
JHEP Rep
February 2025
Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Background & Aims: Large-scale studies on the association between primary biliary cholangitis (PBC) and hepatocellular carcinoma (HCC) in Asians are scarce. This study aimed to evaluate the incidence of HCC and its risk factors in a nationwide cohort.
Methods: The data of 4,882 patients with PBC and 38,603 matched controls were extracted from the Korean National Health Insurance Service (2007-2020) and analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!